TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of Participants With Long-term Stable Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean intravenous glucose infusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success of Needle Placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone marrow toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Serotoninergic syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Retrobulbar optic nevritis
Endpoint domain: Adverse events/effects
Primary endpoint: Physical activity function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fahn-Tolosa-Marin Essential Tremor Rating Scale (FTM) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma concentration of fexinidazole and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpartum flare incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of Venothromboembolism (VTE)
Endpoint domain: Mortality/survival
Primary endpoint: dose-limited toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Meal-regulated insulin time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of subjects who reach the lipid goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of subjects who meet the HbA1c goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Retinal vessel diameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized Number of All Bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cumulative incidence of atopic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Weight Loss (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average cancer-related pain intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological changes in: pupil diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Physiological changes in: blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness outcomes of OXYRX treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of OXYRX treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of identifying L3/L4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perioperative Mortality
Endpoint domain: Mortality/survival
Primary endpoint: changes in cerebral tissue oxygen saturation (SctO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Time Glucose Levels Were > 180 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent of Time <54 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of conjunctival flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bacterial resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Contamination rate of endodontically treated teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Periapical lesion relapse of endodontically treated teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Presence of exudate between treatment sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction of sexual risk behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects With Improved or Stable Composite Visual Analog Scale (VAS) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Attacks Treated With Standard of Care Acute Attack Medication (SOC-Rx) Through 24 Hours
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of ventilator free hours and days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Significant Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Bone formation on interface between bone tunnel and graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days of Mechanical Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inflammation in the spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: System Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: System Related adverse device effects
Endpoint domain: Adverse events/effects
Primary endpoint: Change in 24-hour average blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: modified risk of central demyelination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: modified risk of type 1 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: modified risk of cutaneous Lupus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: modified risk of inflammatory arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: modified risk of idiopathic thrombocytopenic purpura
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: modified risk of systemic lupus erythematosus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Death or Myocardial Infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Minor Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Airway colonization with pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ability to smell
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurofilament Light Chain Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Geometric mean titer (GMT) to vaccine HPV serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sero-response rate to vaccine HPV serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in DAS28(ESR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bidimensionally measurable lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of target-lesion failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in delayed hypersensitivity skin-test (DTH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Knowledge Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Decision Self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Certainty about Choice (Decisional Conflict Scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Major adverse event rate
Endpoint domain: Adverse events/effects
Primary endpoint: Motor skill learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Cardiovascular death or new myocardial Infarction
Endpoint domain: Mortality/survival
Primary endpoint: Composite of cardiovascular death, new myocardial infarction or ischemia-driven revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Clinical Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of Time to Return to Full Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Patients with dose limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Test result of OSOM BVBLUE Test or SavvyCheck Vaginal Yeast Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Inhalative dose of fluticasone propionate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change In Cumulative Meal-related Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Experiencing Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of days with headache
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change From Baseline in Percent Atheroma Volume (PAV) to Month 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: USPIO-enhanced MRI signal in carotid plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Change in Global Cerebral Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Heart failure incidence
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Achieving SRI-4 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) of nasal virus shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Evidence of a 4-fold or greater increase in HAI or MN antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity and specificity of the convolutional neural network
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percentage of active TB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Overall Survival at 18 Months
Endpoint domain: Mortality/survival
Primary endpoint: Change in Numerical rating scale (NRS) for neck pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of Hypophosphatemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in 24-hr SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tacrolimus Area Under the curve at 24 hours (AUC24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tacrolimus Minimum whole blood concentration (Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tacrolimus Cmin/daily dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in 11-point Numerical Rating Scale (NRS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Uptake of HIV testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Evolution of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ischemic driven target vessel revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage change in total body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recurrence-free survival (RFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Change on Health-related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: BOLD Activations in Prespecified ROIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Feelings of Connection
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative Rescue Analgesia requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Hispanic patients beginning depression treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: Maximum Observed Plasma Concentration for TAK-906
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-906
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-906
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of non-cavitated proximal caries lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor vessel diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologic complete resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: APB motor thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total power required for APB motor thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latency times for leg motor thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg motor thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor evoked potentials (MEPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound Apposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum Concentration (Cmax) of LY2835219
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Time Curve AUC(0-∞) of LY2835219
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child's rating of pain on venipuncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Preference Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient-reported medication adherence to four therapies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent of Patients Adherent to four therapies via refill records
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IPSS at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in calcium values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Folate levels in erythrocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean change of the Mean transit time from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change of the Peak intensity from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change of the time to Peak intensity from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change of the Area under the curve from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Testing cerebral autoregulation: Transient Hyperemic test- Absence or presence from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change of the optic nerve sheath diameter from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MPA-PK (AUC0-12hrs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety / Tolerability of Device
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life related to stoma
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Grading of dacryostenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of mother-to-child transmission of HBV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: rate of birth defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Survival rate of the Gemini SL Fixed Bearing knee prosthesis
Endpoint domain: Mortality/survival
Primary endpoint: Dietary glycemic index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Risk factors log response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving PASI-90 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in score of knowledge and ability related to nutritional care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Psychosocial welfare
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mechanical Pain Threshold (MPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Upon Numeric Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Care transition measure 3
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Menstrual cycle maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of Participants Who Experienced an Infusion Reaction (IR), Including Anaphylaxis
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Clinically Significant Changes in Cardiovascular Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Dose limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: maximum tolerated dosage
Endpoint domain: Adverse events/effects
Primary endpoint: toxicity assessment
Endpoint domain: Adverse events/effects
Primary endpoint: 12-month Disease-Free Survival (DFS) Rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Who Experience an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: BK Viral Status in Saliva at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: BK Viral Status in Saliva at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cmax of levodopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in ADP Stimulated P-selectin Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of abnormal and clinical significant measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain as measured by Visual Analogue Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Incidence and grading of local skin reactions as by CTCAE v. 4.03
Endpoint domain: Adverse events/effects
Primary endpoint: Carpal Tunnel Syndrome Symptom Severity and Functional Status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety and tolerability of GS-6615
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic (PK) profile of GS-6615
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unilateral analgesic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Guideline adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acute Tolerability as Measured by Pulmonary Function Test (PFT) Changes Pre to Post Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Serum Creatinine Throughout the Study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Change in Optical Cerebral Blood Flow (oCBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Psoriatic arthritis remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Symptoms of Post-traumatic Stress Disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Symptoms of Anxiety and Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Radiological examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periodontal health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental health problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing